Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company that develops and commercialises medicines for rare neuromuscular and mitochondrial diseases. Its main product is idebenone, marketed as Raxone, which is used to treat Leber's hereditary optic neuropathy, a rare inherited form of vision loss. The company also works on treatments for Duchenne muscular dystrophy and other mitochondrial conditions. Santhera is based in Pratteln, Switzerland, and serves patients and clinicians in specialised rare-disease markets.
On this site Santhera Pharmaceuticals Holding AG appears as a stock on the SIX Swiss Exchange (Switzerland), code SANN, with prices in Swiss francs (CHF). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Weak price profile
Ranks #161 of 226 on the SIX Swiss Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Switzerland yet.
TrendWeak
37/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-2.9%
From 52-week high-18.8%
MomentumWeak
47/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-1.3%
6-month return-18.0%
12-month, skipping last month43.6%
Stability (higher is calmer)Weak
30/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)50.2%
Worst drawdown, 1 year (smaller is calmer)-26.1%
LiquidityWeak
49/100
Thinly traded: prices can jump and exits can be hard.
See the numbers →
Avg daily value traded1.16M CHF
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Switzerland when fundamentals data for this market is added. All Switzerland stocks.
52-wk range 10.06 – 18.84Daily closes, split-adjusted
Signals
50-day average15.28
200-day average15.50
Golden/death cross (60d)Death, 6 days ago
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.63
Technical summary
Daily
Neutral
7 bullish · 2 neutral · 7 bearish
Weekly
Neutral
6 bullish · 1 neutral · 5 bearish
Monthly
Strongly bullish
6 bullish · 1 neutral · 1 bearish
Moving averages (daily)
SMA 10
14.43
Bullish
EMA 10
14.48
Bullish
SMA 20
14.61
Bullish
EMA 20
14.64
Bullish
SMA 50
15.28
Bearish
EMA 50
15.02
Bullish
SMA 100
15.33
Bearish
EMA 100
15.24
Bearish
SMA 200
15.50
Bearish
EMA 200
15.02
Bullish
Oscillators (daily)
RSI (14)
53.16
Neutral
MACD (12, 26)
-0.24
Bearish
Momentum (12)
5.46
Bullish
Stochastic %K (14)
97.62
Bearish
Williams %R (14)
-2.38
Bearish
CCI (20)
39.23
Neutral
Pivot points (classic, last session)
S3
14.01
S2
14.23
S1
14.65
Pivot
14.87
R1
15.29
R2
15.51
R3
15.93
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in CHF. Educational only, not financial advice.
